NCHR Comments to FDA on Nicotine Replacement Therapy (NRT) Product Uses and Labeling Changes

FDA, February 15, 2018. It remains unclear whether individual achievement of abstinence is sustainable over time and whether long-term NRT use is more or less beneficial on an individual or population health level. We commend the FDA for addressing their role in developing strategies to evaluate NRT products and labeling. We agree that urgent action is necessary and the FDA should consider science-based approaches to reduce further harm from combustible tobacco products.

Read More »
Page 1 of 212